Cyclosporin A liposome aerosol: Particle size and calculated respiratory deposition

Waldrep, J. Clifford; Scherer, Peter; Keyhani, Keyvan; Knight, Vernon

doi:10.1016/0378-5173(93)90140-b

Cited by 43 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The induction port was used to collect aerosol particles that did not pen- mass) as the abscissa (Kaleida Graph 3.51) as previously described. 19,20 The MMAD metrics were used as measure of central tendency. The RF and FPF were calculated as the percentage of aerosolized albuterol at Ͻ5.0 and Ͻ3.3 m, respectively.…”

Section: Aerosol Particle Size Distribution By Cascade Impaction By Amentioning

confidence: 99%

Comparative Analysis of Methods to Measure Aerosols Generated by a Vibrating Mesh Nebulizer

Waldrep

Berlinski

Dhand

2007

Journal of Aerosol Medicine

Self Cite

View full text Add to dashboard Cite

Different approaches have been employed for in vitro assessment of the aerosol particle size generated by inhalation devices. In this study, aerosols from the Omron MicroAir vibrating mesh (VM) nebulizer were measured by cascade impaction (CI) using the MSP Next Generation Pharmaceutical Impactor (NGI), the ThermoAndersen Cascade Impactor (ACI), and by time-of-flight (TOF) analysis with the TSI 3321 Aerodynamic Particle Sizer Spectrometer (APS). The VM nebulizer was evaluated with sodium fluoride (NaF; 2.5%) and with generic albuterol (0.083%). Aerosol particle size (MMAD), respirable fractions (RF < 5 microm), and fine particle fractions (FPF < 3.3 microm) were determined with each method at room temperature (RT) and 4 degrees C using 50% average relative humidity. By NGI at either RT or 4 degrees C, aerosol particle sizes were similar for both NaF and albuterol (4.3-4.5 microm MMAD) with 55-61% RF and 27-43% FPF. With ACI, the distribution of particles at RT was similar except at the extremes of the dispersion and the MMAD was smaller (3.3 microm MMAD; p = 0.03). At 4 degrees C, particle sizes determined by ACI results were similar to the NGI (MMAD 4.1 microm; p > 0.05). TOF analysis by APS with albuterol gave significantly larger calculated MMAD (cMMAD) than either CI method (7.2 microm; p < 0.001). TOF measurements of nebulized albuterol at RT and 4 degrees C were equivalent. In summary, the results of VM nebulized NaF and albuterol were more consistent and generally equivalent when determined by NGI (at RT and 4 degrees C) and ACI analysis (at 4 degrees C). In contrast, aerosol particle sizes measured by TOF in the APS at both RT and 4 degrees C were larger than results obtained by CI. Differences in aerosol particle distribution obtained by different analysis methods should be considered while evaluating the in vitro performance of VM nebulizers.

show abstract

Section: Aerosol Particle Size Distribution By Cascade Impaction By Amentioning

confidence: 99%

Comparative Analysis of Methods to Measure Aerosols Generated by a Vibrating Mesh Nebulizer

Waldrep

Berlinski

Dhand

2007

Journal of Aerosol Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 As a calcineurin inhibitor, it blocks lymphocyte activation by inhibiting transcription of cytokine genes in a dose-dependent manner. [1][2][3] In addition, CsA has therapeutic effects on the prevention of allograft rejection after lung transplantation. 4,5 The systemic effects associated with CsA are substantial, including hypertension and most notably renal toxicity.…”

Section: Introductionmentioning

confidence: 99%

“…[1][2][3] As a calcineurin inhibitor, CsA reversibly inhibits T-cell mediated immune response, including the synthesis of interleukin-2, interleukin-6, and interferon-γ. 3 As a calcineurin inhibitor, it blocks lymphocyte activation by inhibiting transcription of cytokine genes in a dose-dependent manner.…”

Section: Introductionmentioning

confidence: 99%

Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery

Wu¹,

Zhang²,

Hayes³

et al. 2013

IJN

View full text Add to dashboard Cite

Abstract:In this systematic and comprehensive study, inhalation powders of the polypeptide immunosuppressant drug -cyclosporine A -for lung delivery as dry powder inhalers (DPIs) were successfully designed, developed, and optimized. Several spray drying pump rates were rationally chosen. Comprehensive physicochemical characterization and imaging was carried out using scanning electron microscopy, hot-stage microscopy, differential scanning calorimetry, powder X-ray diffraction, Karl Fischer titration, laser size diffraction, and gravimetric vapor sorption. Aerosol dispersion performance was conducted using a next generation impactor with a Food and Drug Administration-approved DPI device. These DPIs displayed excellent aerosol dispersion performance with high values in emitted dose, respirable fraction, and fine particle fraction. In addition, novel multifunctional inhalation aerosol powder formulations of cyclosporine A with lung surfactant-mimic phospholipids were also successfully designed and developed by advanced organic solution cospray drying in closed mode. The lung surfactantmimic phospholipids were 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-snglycero-3-(phosphor-rac-1-glycerol). These cyclosporine A lung surfactant-mimic aerosol powder formulations were comprehensively characterized. Powder X-ray diffraction and differential scanning calorimetry confirmed that the phospholipid bilayer structure in the solid state was preserved following advanced organic solution spray drying in closed mode. These novel multifunctional inhalation powders were optimized for DPI delivery with excellent aerosol dispersion performance and high aerosol performance parameters.

show abstract

“…The probable and potent benefits from targeted lung delivery are the decreased systemic toxicity and the persistent immunosuppressive action. Aerosol delivery systems are settled at the lung disease site to settle down the drugs on the pulmonary surfaces [61]. The new HPLC method established by Waldrep et al [62] was used for tissue investigation of (CsA)-liposomes, and to measure cyclosporine-A retrieved from BALB/ c mouse lung tissues.…”

Section: The Effectiveness Of Pulmonary Targeting Of the Csa-dlpc Lipmentioning

confidence: 99%

Liposome as nanocarrier: Site targeted delivery in lung cancer

Ullah¹,

Noreen²,

Tehreem³

et al. 2017

APJTD

View full text Add to dashboard Cite

Cyclosporin A liposome aerosol: Particle size and calculated respiratory deposition

Cited by 43 publications

References 18 publications

Comparative Analysis of Methods to Measure Aerosols Generated by a Vibrating Mesh Nebulizer

Comparative Analysis of Methods to Measure Aerosols Generated by a Vibrating Mesh Nebulizer

Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery

Liposome as nanocarrier: Site targeted delivery in lung cancer

Contact Info

Product

Resources

About